Skip to main content
. 2013 Jan;27(1):313–321. doi: 10.1096/fj.12-213454

Figure 1.

Figure 1.

Adenoviral delivery of Atgl shRNA increases whole-body glucose tolerance without altering hepatic insulin signaling. A, B) Serum glucose (A) and insulin (B) levels were measured 7 d after control shRNA (cont shRNA) or Atgl shRNA administration in mice fed a control or HF diet (n=6–10). C, D) Following adenovirus administration, mice were fed an HF diet for 6 d, followed by overnight food withdrawal prior to OGTT (C) and ITT (D) and respective AUC graphs (n=5). E) Hepatic insulin signaling was assessed by immunoblotting to determine insulin-stimulated phosphorylation of Akt and IRS1in mice fed an HF diet for 7 d (n=6–10). *P < 0.05 vs. control shRNA group; #P < 0.05 vs. control diet group or saline-injected group.